摘要
心血管疾病是新型冠状病毒肺炎(新冠肺炎)最为常见的合并症,在新冠肺炎大流行期间降压、降脂、抗血小板、抗凝、降糖及抗心律失常等心血管系统常用药物的安全性和有效性尚未形成统一明确的认识,相关指南也有待进一步完善。随着全球新冠肺炎病例数量的增加和第二波感染的发生,更好地了解这些药物对新冠肺炎患者的影响是当务之急。本文旨在总结心血管系统常用药物对新冠肺炎感染风险以及不良预后的关联,并对合并心血管疾病的新冠肺炎患者用药提出建议。
Cardiovascular disease is the most-common complication of coronavirus disease 2019(COVID-19).During the COVID-19 pandemic,the safety and efficacy of common cardiovascular drugs such as anti-hypertensive,lipid-lowering,antiplatelet,anticoagulant,hypoglycemic and antiarrhythmic drugs have remained controversial that required improved consensuses.With the increase of global cases of COVID-19 and the occurrence of the second wave of infection,it is urgent to reveal the effects of cardiovascular disease drugs on COVID-19 patients.This study aims to summarize the relationship between common cardiovascular drugs and the risk of COVID-19 infection and poor prognosis,thus providing references for medications in COVID-19 patients with cardiovascular diseases.
作者
周子涵
崔炜
Zhou Zihan;Cui Wei(First Department of Cardiology,the Second Hospital of Hebei Medical University and Institute of Cardiocerebrovascular Disease of Hebei Province,Shijiazhuang 050000,China)
出处
《临床荟萃》
CAS
2022年第10期869-888,共20页
Clinical Focus
关键词
新型冠状病毒肺炎
心血管系统
抗凝治疗
抗血小板治疗
降脂治疗
降压治疗
降糖治疗
抗心律失常
荟萃分析
COVID-19
cardiovascular system
anticoagulant therapy
antiplatelet therapy
lipid-lowering therapy
anti-hypertensive therapy
hypoglycemic therapy
antiarrhythmic therapy
meta-analysis
